Sign up
Pharma Capital

Regeneus CEO taking part in delegation to Japan

John Martin will present to over 60 pharmaceutical and healthcare companies.
shutterstock_272536982-001.jpg
The company's flagship asset is Progenza

Regeneus (ASX:RGS) CEO John Martin  will be participating in Austrade’s business delegation to Japan on April 18 and 19 being led by Australia’s minister for trade, tourism and investments.

Austrade is the Australian government’s export, international education and foreign investment promotion agency.

The two-day mission will showcase leading Australian capabilities in a range of key sectors including regenerative medicine which is an area of particular interest in Japan.

Martin will present the company’s portfolio of clinical-stage regenerative medicine therapies and proprietary technology platforms to over 60 attending Japanese pharmaceutical and healthcare companies.

Regeneus is an emerging leader in cell based medicines for both humans and animals.

Its flagship asset, Progenza is a patented off-the-shelf stem cell technology developed for the treatment of knee osteoarthritis and other inflammatory conditions.

Regeneus recently entered into a strategic partnership and licensing agreement with Asahi Glass Co Ltd (TYO:5201) for the manufacture, clinical development and commercialisation of Progenza in Japan.

AGC will be the exclusive manufacturer of Progenza in Japan and the joint venture company ‘Regeneus Japan’ will be established for the exclusive licensing of the clinical development and marketing rights of Progenza in Japan.

The Japanese market offers significant growth opportunities for Regeneus and Japanese businesses are looking to Australia for solutions in response to the implementation of the Japan Australia Economic Partnership Agreement.

The market in Japan for regenerative medicines is projected to grow to US$12.7 billion by 2030 and is one of the pillars of growth under the current government.

View full RGS profile

Regeneus Ltd Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.